Biofrontera(NASDAQ) BFRIW

Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. The company offers innovative products aimed at treating conditions such as actinic keratosis and impetigo, leveraging advanced photodynamic therapy technologies.

Products and Services

• Ameluz: A prescription drug for photodynamic therapy
• BF-RhodoLED: A lamp series used in conjunction with Ameluz
• Xepi: A topical treatment for impetigo

Growth Outlook

• Recent quarterly revenue reached $10.08 million, indicating strong market demand
• Gross profit margin improved to 82% in Q1 2026, showcasing operational efficiency
• Expansion into new markets is anticipated to drive future revenue growth

Financial Highlights

• Trailing twelve months (TTM) revenue of $49.5 million reflects a significant increase
• Net income for Q4 2025 was $5.64 million, marking a profitable quarter
• Cash and cash equivalents stood at $6.32 million as of March 31, 2026

Biofrontera Inc. has established itself as a key player in the biopharmaceutical industry, focusing on skin-related treatments. The company's flagship product, Ameluz, combined with the BF-RhodoLED lamp, offers a unique solution for actinic keratosis, a common skin condition. The introduction of Xepi further diversifies the product portfolio, addressing the need for effective treatments for impetigo. The growth outlook for Biofrontera is promising, with recent quarterly revenue demonstrating strong demand for its products. The improvement in gross profit margin indicates effective cost management and operational efficiency. Additionally, the company's plans for market expansion are expected to contribute positively to future revenue streams. Financially, Biofrontera has shown resilience, with a notable revenue increase over the trailing twelve months. The recent profitability in Q4 2025 highlights the company's ability to generate income, while a solid cash position provides a buffer for ongoing operations and potential investments. Overall, Biofrontera Inc. presents an intriguing opportunity for investors interested in the biopharmaceutical sector.